文献速递运动医学

运动医学中生物治疗当前使用的实用指南

A Practical Guide for the Current Use of Biologic Therapies in Sports Medicine.
PubMed 文献 · Am J Sports Med · 2019-04-30

该文指出过去十年运动医学中富血小板血浆、骨髓抽吸浓缩液等生物治疗的使用、营销和患者需求显著增加,但缺乏高质量疗效证据,保险多视为实验性,患者常自付高额费用;需理解FDA最新指南,且制备、来源、递送方法和剂量缺乏共识;未来研究需明确生物靶点、改进报告标准并整合多方。

要点

  • 生物治疗(富血小板血浆、骨髓抽吸浓缩液等)在运动医学中使用增加,但证据质量不高。
  • 多数保险公司因缺乏高质量证据将骨科生物治疗视为实验性或研究性,患者常需自付高额费用。
  • 生物治疗的最佳制备、来源、递送方法和剂量缺乏共识,且多数已发表研究缺乏足够实验细节。

核心结论

  • 生物治疗在运动医学中的应用增加,但缺乏高质量疗效证据,需准确传达安全性和有效性。
  • 未来研究必须更好地确定治疗的生物靶点、遵循更好的报告标准,并更好地整合研究者、产业和监管机构以优化应用。

研究设计与样本

  • 原文未报告。

主要发现

  • 过去十年运动医学中生物治疗的使用兴趣增加,包括富血小板血浆、骨髓抽吸浓缩液和其他细胞衍生治疗。
  • 生物治疗的市场营销、患者需求和临床利用显著增加。
  • 直接面向消费者的生物治疗营销激增但基本不受监管。
  • 大多数保险公司因缺乏高质量疗效证据将骨科生物治疗视为实验性或研究性,患者常自付高额费用。
  • 提供生物治疗的各中心治疗费用存在范围差异,需要适当和可持续的定价与报销模型。

关键数值与推荐

  • 原文未报告。

临床怎么用

  • 临床医生必须向患者准确传达这些疗法的安全性和有效性特征。
  • 使用生物治疗的临床医生必须透彻理解最近澄清的FDA指南,该指南监管细胞和组织产品的临床使用。
  • 原文未据此给出推荐。

局限性

  • 缺乏高质量证据支持生物治疗在骨科应用中的疗效。
  • 生物治疗的最佳制备、来源、递送方法和剂量缺乏共识。
  • 大多数已发表研究缺乏足够的实验细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past decade, there has been an increased interest in the use of biologic therapies in sports medicine. Although these technologies are in relatively early stages of development, there have been substantial increases in marketing, patient demand, and clinical utilization of biologics, including platelet-rich plasma, bone marrow aspirate concentrate, and other cell-derived therapies. Direct-to-consumer marketing of biologics has also proliferated but is largely unregulated, and clinicians must accurately convey the safety and efficacy profiles of these therapies to patients. Because most insurance companies consider biologic treatments to be experimental or investigational for orthopaedic applications given the lack of high-quality evidence to support their efficacy, patients receiving these treatments often make substantial out-of-pocket payments. With a range of treatment costs among centers offering biologics, there is a need for appropriate and sustainable pricing and reimbursement models. Clinicians utilizing biologics must also have a thorough understanding of the recently clarified Food and Drug Administration guidelines that regulate the clinical use of cell and tissue products. There is a lack of consensus on the optimal preparation, source, delivery method, and dosing of biologic therapies, which has been exacerbated by a lack of sufficient experimental detail in most published studies. Future research must better identify the biologic target of treatment, adhere to better standards of reporting, and better integrate researchers, industry, and regulatory bodies to optimize applications.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Lamplot JD, Rodeo SA, Brophy RH, et al. A Practical Guide for the Current Use of Biologic Therapies in Sports Medicine. Am J Sports Med. 2019. PMID: 31038990. doi:10.1177/0363546519836090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。